Luxeptinib, co-developed by Crystalgenomics Inc. and Aptose, is investigated for its potential in treating various conditions, including myelodysplastic syndrome (MDS), CLL, acute myeloid leukemia (AML), and NHL in clinical phase I. Luxeptinib is a non-covalent, reversible, and orally active inhibitor that targets both fms-like tyrosine kinase (FLT3) and BTK [52]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.